Avenu Medical
Other, Calle Arroyo, San Juan Capistrano, , 92675, California, 27123, United States, 11-50 Employees
Phone Number: 94********
Who is AVENU MEDICAL
Avenu Medical is a well-established medical device company dedicated to creating a paradigm shift in vascular access for hemodialysis patients. Our focus is to pursue unmet clinical needs...
Read More
-
Headquarters: 27123 Calle Arroyo, San Juan Capistrano, California, 92675, United States
-
Date Founded: 2010
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Other
SIC Code: 3841
Does something look wrong? Fix it. | View contact records from AVENU MEDICAL
Avenu Medical Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Avenu Medical
Answer: Avenu Medical's headquarters are located at Calle Arroyo, San Juan Capistrano, , 92675, California, 27123, United States
Answer: Avenu Medical's phone number is 94********
Answer: Avenu Medical's official website is https://avenumedical.com
Answer: Avenu Medical's revenue is $5 Million to $10 Million
Answer: Avenu Medical's SIC: 3841
Answer: Avenu Medical has 11-50 employees
Answer: Avenu Medical is in Other
Answer: Avenu Medical contact info: Phone number: 94******** Website: https://avenumedical.com
Answer: Avenu Medical is a well-established medical device company dedicated to creating a paradigm shift in vascular access for hemodialysis patients. Our focus is to pursue unmet clinical needs by developing a minimally invasive, cost effective and efficient approach to vascular access. Founded in 2010 and headquartered in Orange County, California, we have developed the Ellipsys Vascular Access System, an innovative, image-guided, single catheter system used to percutaneously create an arteriovenous (AV) fistula for hemodialysis access. Over the past three years, the Ellipsys System has been used in clinical trials outside the United States. In December 2014, we received approval from the Food and Drug Administration (FDA) to begin a pivotal Phase III clinical trial in the United States through an Investigational Device Exemption (IDE). Patient enrollment for the trial was completed in June 2016. The Ellipsys System has received FDA approval and European CE Mark approval for the creation of an arteriovenous fistula in patients with chronic kidney disease requiring hemodialysis.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month